Expand SPRB Menu
SPRB MENU

SPRB Latest Press Releases

-- February 5, 2026 --

Long-Term Data Presented at the 22nd Annual WORLDSymposium Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB) Business Wire 4:05 PM

-- February 3, 2026 --

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team Business Wire 8:00 AM

-- January 28, 2026 --

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium Business Wire 8:00 AM

-- January 18, 2026 --

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration PRNewswire 7:03 PM

-- January 8, 2026 --

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital Business Wire 8:00 AM

-- December 15, 2025 --

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors Business Wire 8:00 AM

-- November 10, 2025 --

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates Business Wire 4:05 PM

-- October 8, 2025 --

Spruce Biosciences Announces $50.0 Million Private Placement Financing Business Wire 8:00 AM

-- October 6, 2025 --

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) Business Wire 8:00 AM

-- September 15, 2025 --

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market Business Wire 7:00 AM
Market Data Delayed 15 Minutes